Abstract：
OBJECTIVE: To determine the prevalence of PIMDINAC criteria and to implement pharmacological interventions in a population with multiple sclerosis over 55 years of age.
METHODS: Retrospective, observational, open-label study, including patients with multiple sclerosis aged 55 years and older during December 2022 and February 2023. The main variable determined was the percentage of compliance with the PIMDINAC criteria.
RESULTS: Ninety-five patients were included, with the presence of PIMDINAC criteria detected in 67.4%. The most frequently detected criterion was non-adherence to concomitant treatment (84.4%), followed by drug-drug interactions (56.2%) and potentially inappropriate medication (25%). A total of 20 pharmaceutical interventions were performed in 17 patients (17.9%). Potentially inappropriate medication was responsible for 11 interventions, non-adherence for 7, and drug-drug interactions for 2. The 81.8% of interventions were accepted, resulting in the discontinuation of 15 inappropriately prescribed drugs. The prevalence of PIMDINAC criteria in this group of patients is high. The study revealed that PIMDINAC criteria were prevalent in 67.4% of the study population, with polypharmacy playing an important role, suggesting the potential for a multidisciplinary approach, through pharmaceutical interventions to address unnecessary or duplicate treatments.
METHODS: Retrospective, observational, open-label study, including patients with multiple sclerosis aged 55 years and older during December 2022 and February 2023. The main variable determined was the percentage of compliance with the PIMDINAC criteria.
RESULTS: Ninety-five patients were included, with the presence of PIMDINAC criteria detected in 67.4%. The most frequently detected criterion was non-adherence to concomitant treatment (84.4%), followed by drug-drug interactions (56.2%) and potentially inappropriate medication (25%). A total of 20 pharmaceutical interventions were performed in 17 patients (17.9%). Potentially inappropriate medication was responsible for 11 interventions, non-adherence for 7, and drug-drug interactions for 2. The 81.8% of interventions were accepted, resulting in the discontinuation of 15 inappropriately prescribed drugs. The prevalence of PIMDINAC criteria in this group of patients is high. The study revealed that PIMDINAC criteria were prevalent in 67.4% of the study population, with polypharmacy playing an important role, suggesting the potential for a multidisciplinary approach, through pharmaceutical interventions to address unnecessary or duplicate treatments.
摘要：
目的：确定PIMDINAC标准的患病率，并在55岁以上的多发性硬化症患者中实施药物干预措施。
方法：回顾性，观察,开放标签研究，包括2022年12月和2023年2月期间55岁及以上的多发性硬化症患者。确定的主要变量是符合PIMDINAC标准的百分比。
结果：纳入95例患者，与PIMDINAC标准的存在检测67.4%。最常见的检测标准是不遵守伴随治疗（84.4％），其次是药物-药物相互作用(56.2%)和潜在的不适当用药(25%).17例患者（17.9%）共进行了20项药物干预。不适当的药物可能导致11种干预措施，不依从性为7，药物-药物相互作用为2。81.8%的干预措施被接受，导致15种不适当的处方药停止使用。PIMDINAC标准在该组患者中的患病率很高。研究表明，PIMDINAC标准在67.4%的研究人群中普遍存在，在多元化药物发挥重要作用的情况下，暗示了多学科方法的潜力，通过药物干预来解决不必要或重复的治疗。
方法：回顾性，观察,开放标签研究，包括2022年12月和2023年2月期间55岁及以上的多发性硬化症患者。确定的主要变量是符合PIMDINAC标准的百分比。
结果：纳入95例患者，与PIMDINAC标准的存在检测67.4%。最常见的检测标准是不遵守伴随治疗（84.4％），其次是药物-药物相互作用(56.2%)和潜在的不适当用药(25%).17例患者（17.9%）共进行了20项药物干预。不适当的药物可能导致11种干预措施，不依从性为7，药物-药物相互作用为2。81.8%的干预措施被接受，导致15种不适当的处方药停止使用。PIMDINAC标准在该组患者中的患病率很高。研究表明，PIMDINAC标准在67.4%的研究人群中普遍存在，在多元化药物发挥重要作用的情况下，暗示了多学科方法的潜力，通过药物干预来解决不必要或重复的治疗。
